IA-WORKIVA
Workiva (NYSE:WK), a leader in cloud-based data collaboration, reporting and compliance solutions, today announced it has signed an original equipment manufacturer (OEM) agreement with SAP (NYSE:SAP).
Through this agreement, Workiva is partnering with SAP to provide a first-party integration with the Wdesk platform using the SAP® Cloud Platform Integration service. The bundled solutions are expected to provide customers with powerful linking, auditability and control features.
“Today’s announcement demonstrates that Workiva and SAP are committed to providing customers with a rich integration experience,” said Matt Rizai, chairman and CEO of Workiva. “Through our OEM partnership, we will help customers all over the world improve the value of their business data.”
After users integrate their SAP business data directly into the Wdesk platform, they can benefit from the full capabilities of Wdesk, including synchronized data, dynamic commentary, controlled collaboration, granular permissions and clear audit trails. Wdesk enables narrative to be linked to data across documents, spreadsheets, presentations and reports.
Customers will be able to rely on the data transparency and consistency that Wdesk provides to help mitigate risk and have confidence in their data-driven decisions.
“SAP customers across every industry are looking to leverage cloud technology to improve data collaboration, reduce costs and gain greater business insights,” said Diane Fanelli, senior vice president, Platform Channels at SAP. “Our partnership with Workiva will help our customers improve data integrity and drive better business performance.”
About Workiva
Workiva delivers Wdesk, a leading enterprise cloud platform for data collaboration, reporting and compliance that is used by thousands of organizations worldwide, including over 70 percent of the Fortune 500® . Companies of all sizes, state and local governments and educational institutions use Wdesk to help mitigate risk, improve productivity and gain confidence in their data-driven decisions. For more information about Workiva (NYSE:WK), please visit workiva.com .
Read the Workiva blog: www.workiva.com/blog
Follow
Workiva on LinkedIn: www.linkedin.com/company/workiva
Like
Workiva on Facebook: www.facebook.com/workiva/
Follow
Workiva on Twitter: www.twitter.com/Workiva
Claim not confirmed by FORTUNE or TIME INC. FORTUNE® and FORTUNE 500® are registered trademarks of Time Inc. and are used under license. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, Workiva Inc.
Workiva Safe Harbor Statement
Certain statements in this
press release are “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and are
subject to the safe harbor created thereby. These statements relate to
future events or Workiva’s future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, levels of activity, performance or achievements of
Workiva or its industry to be materially different from those expressed
or implied by any forward-looking statements. In particular, statements
about Workiva’s expectations, beliefs, plans, objectives, assumptions,
future events or future performance contained in this press release are
forward-looking statements. In some cases, forward-looking statements
can be identified by terminology such as “may,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “potential,” “outlook,” “guidance” or the
negative of those terms or other comparable terminology. Please see
Workiva’s documents filed or to be filed with the Securities and
Exchange Commission, including the Workiva’s annual reports filed on
Form 10-K and quarterly reports on Form 10-Q, and any amendments thereto
for a discussion of certain important risk factors that relate to
forward-looking statements contained in this report. Workiva has based
these forward-looking statements on its current expectations,
assumptions, estimates and projections. While Workiva believes these
expectations, assumptions, estimates and projections are reasonable,
such forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond Workiva’s
control. These and other important factors may cause actual results,
performance or achievements to differ materially from those expressed or
implied by these forward-looking statements. Any forward-looking
statements are made only as of the date hereof, and unless otherwise
required by applicable securities laws, Workiva disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE (or an SAP affiliate company) in Germany and other countries. See www.sap.com/corporate-en/legal/copyright/index.epx for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.
SAP Forward-looking Statement
Any statements contained in
this document that are not historical facts are forward-looking
statements as defined in the U.S. Private Securities Litigation Reform
Act of 1995. Words such as “anticipate,” “believe,” “estimate,”
“expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,”
“should” and “will” and similar expressions as they relate to SAP are
intended to identify such forward-looking statements. SAP undertakes no
obligation to publicly update or revise any forward-looking statements.
All forward-looking statements are subject to various risks and
uncertainties that could cause actual results to differ materially from
expectations The factors that could affect SAP's future financial
results are discussed more fully in SAP's filings with the U.S.
Securities and Exchange Commission ("SEC"), including SAP's most recent
Annual Report on Form 20-F filed with the SEC. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of their dates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005409/en/
Contact:
Workiva Inc.
Kevin McCarthy, 515-663-4471
press@workiva.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom